ImmunityBio's Stock Rebound and Undervalued Status: A DCF Analysis Perspective

Merck KGaA's recent FDA filing for pimicotinib and earnings beat exceeded forecasts, resulting in a 10.13% 3-month share price return and 7.26% 1-year total shareholder return decline. The company's successful acquisition of SpringWorks and solid pipeline enhance future revenue streams and lay the groundwork for sustained margin expansion in healthcare. Despite potential revenue pressure from Mavenclad patent expiry and softer demand in Electronics and lab-related businesses, the most followed narrative points to a higher fair value for Merck KGaA, with a fair value estimate of €143.88 and an intrinsic discount of 56.60%.